Joseph P. Catlett, MD; Barbara M. Alving, MD
Requests for Single Reprints: Joseph P. Catlett, MD, Hematology/Oncology Section, Washington Hospital Center, 110 Irving Street NW, Washington, DC 20010-2975.
Current Author Addresses: Dr. Catlett: Hematology/Oncology Section, Washington Hospital Center, 110 Irving Street NW, Washington, DC 20010-2975.
Dr. Alving: National Heart, Lung, and Blood Institute, National Institutes of Health, Building 31, Room 5A 47, 10 Center Drive, Bethesda, MD 20892-2490.
Catlett JP, Alving BM. Update in Hematology. Ann Intern Med. 2002;136:136-143. doi: 10.7326/0003-4819-136-2-200201150-00011
Download citation file:
Published: Ann Intern Med. 2002;136(2):136-143.
In the past several years, there has been a veritable explosion of new and impressive treatments that not only will alter the management of leukemia and lymphoma but are expected to have far-reaching effects in general internal medicine. Target-specific drugs, including monoclonal antibodies and selective enzyme inhibitors—along with so-called designer drugs—have ushered in a new era in medicine. Examples in this Update are rituximab, a monoclonal antibody effective in non-Hodgkin lymphoma and the oral antileukemia drug STI-571. We also discuss advances in the following areas of hematology: self-management of oral anticoagulant therapy, understanding risks for venous thromboembolism in women during pregnancy and in postmenopausal women who are undergoing hormone replacement therapy, and management of patients with sickle-cell disease.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only